Lacey, WA – April 26, 2005 – Unigen Pharmaceuticals, Inc., a leading research and development facility and supplier of proprietary, biologically active plant-derived ingredients to the natural products and pharmaceutical industries, has announced that the U.S. Patent and Trademark Office today issued a composition of matter and usage patent for the company’s proprietary antioxidant ingredients contained in its Aloewhite® and Pervarin® commercial raw material ingredient products.
"Aloewhite® and Pervarin® are two important commercial products derived from the aloe chromone molecules cited in this patent,” said Dr. Qi Jia, Unigen’s Chief Scientific Officer and co-inventor of the patent. “Aloewhite® contains more than 90% aloesin, and can be formulated into anti-aging and sun care cosmetic products. Pervarin® contains a significant amount of aloeresin A and, through oral or topical administration, can support the body’s endogenous antioxidation functions against damage caused by lipid peroxidation." He added, “This utility patent will offer protection to Unigen's intellectual property and will enhance the product value for our business partners."
Through the identification and purification of specific aloe chromones derived from Aloe vera and other plant species, Unigen scientists have demonstrated the effectiveness of these chromones in inhibiting free radical and oxidative damage through the simultaneous suppression of free radical generation and production of Reactive Oxygen Species (ROS), which includes oxygen-related free radicals.
ROS involves a normal physiological process responsible for a variety of healthy bodily functions. This includes immune and inflammation response, and the intercellular induction of apoptosis, a form of cell death necessary to allow for new cell production, as well the removal from the body of cells with damaged DNA. However, an overproduction of ROS is a major inducer of the aging process that may lead to wrinkled skin, as well as other health concerns such as atherosclerosis, coronary heart disease, dementia, cognitive dysfunction, diabetes mellitus, cancer and melanoma, particularly if ROS is generated as a by-product of food additives, ultraviolet radiation, and exposure to tobacco smoke and other pollutants.
Unigen’s patent disclosed that aloesin, an aloe chromone, had a much higher Oxygen Radical Absorbance Capacity (ORAC) than standardized green tea and grape seed extracts. Another chromone, aloeresin A, was four times more potent as a fast-acting antioxidant than the standardized green tea and grape seed extracts. Aloeresin A was also shown to be a stronger antioxidant than either a tocopherol or vitamin C as measured by lipid peroxidation inhibition capacity. Aloeresin A inhibited lipid peroxidation and was shown to be three times more potent than Vitamin E, even at a low concentration.
# # #
About Unigen Pharmaceuticals, Inc.
Unigen Pharmaceuticals, Inc. (www.unigenpharma.com) is a leading natural products research and development company and proprietary ingredients supplier. The company is dedicated to the discovery of botanically derived therapeutic compounds that address consumer health needs and help improve the quality of human life. Its research and discovery process includes extensive work at both the human cell and gene level. Unigen and sister company Aloecorp, Inc. each focus on identifying and studying the unique ingredients of medicinal botanicals (Aloecorp’s focus is on Aloe vera) and then formulating proprietary raw materials for use in cosmeceutical, nutraceutical and pharmaceutical products.
Regan Miles, Executive Vice President
Unigen Pharmaceuticals, Inc.